TOKYOOtsuka Pharmaceutical Co agreed to buy Avanir Pharmaceuticals Inc of the US for  billion the latest large deal by a Japanese drug maker looking to expand overseas The deal gives Otsuka maker of the schizophrenia and depression drug Abilify access to more treatments for centralnervoussystem diseases Californiabased Avanir sells Nuedexta a treatment for a condition known as pseudobulbar affect that causes sudden and involuntary outbursts in patients with neurological diseases such as amyotrophic lateral
  